Edition:
India

Fresenius Medical Care AG & Co KGaA (FMEG.DE)

FMEG.DE on Xetra

70.70EUR
8:39pm IST
Change (% chg)

€-0.10 (-0.14%)
Prev Close
€70.80
Open
€70.88
Day's High
€71.44
Day's Low
€69.68
Volume
617,709
Avg. Vol
806,222
52-wk High
€93.82
52-wk Low
€67.34

Chart for

About

Fresenius Medical Care AG & Co. KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company's segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the... (more)

Overall

Beta: 0.37
Market Cap(Mil.): €25,665.52
Shares Outstanding(Mil.): 307.96
Dividend: 0.96
Yield (%): 1.15

Financials

UPDATE 2-Fresenius Medical Care says expects weaker growth in Q4

* Deadline for NxStage Medical takeover extended (Adds share price, analyst)

30 Oct 2018

Fresenius says working to fix performance at dialysis business, German hospitals

BERLIN, Oct 30 Germany's Fresenius said it was putting measures in place to improve growth at its dialysis and German hospitals businesses after a weaker performance of these units prompted the group to narrow its guidance earlier this month.

30 Oct 2018

Fresenius Medical Care says expects weaker growth in Q4

BERLIN, Oct 30 Germany's Fresenius Medical Care warned it expected slower growth to continue in the fourth quarter after weaker-than-expected growth prompted the group to cut its earnings guidance earlier this month.

30 Oct 2018

FMC takes stake in Humacyte in bet on bioengineered blood vessel

FRANKFURT Germany's Fresenius Medical Care (FMC) has agreed to take a $150 million stake in U.S. tissue engineering firm Humacyte Inc. and will become the exclusive distributor of the company's bioengineered blood vessels once they win approval.

11 Jun 2018

FMC takes stake in Humacyte in bet on bioengineered blood vessel

FRANKFURT, June 11 Germany's Fresenius Medical Care (FMC) has agreed to take a $150 million stake in U.S. tissue engineering firm Humacyte Inc. and will become the exclusive distributor of the company's bioengineered blood vessels once they win approval.

11 Jun 2018

Earnings vs. Estimates